U.S. Study Confirms Long-Lasting Natural Lip Results with RHA® 3

Teoxane announces new U.S. clinical data published in the Aesthetic Surgery Journal confirming that RHA® 3 provides natural-looking, durable lip augmentation with high patient satisfaction and proven safety.

 

Teoxane is proud to announce the publication of new U.S. clinical data in the Aesthetic Surgery Journal showing that RHA® 3 offers safe, natural-looking and durable results in lip augmentation.

The pivotal study was conducted across seven centers in the United States with more than 200 participants. Results demonstrated that RHA® 3:

  • Improves lip fullness in a way that looks and feels natural
  • Maintains results for up to 12 months
  • Provides high patient satisfaction, with over 80% of patients still satisfied at one year
  • Requires fewer touch-ups and less product volume than the comparator filler
  • Shows a favorable safety profile, with no late-onset reactions reported


RHA® 3 combines strength and flexibility, making it ideal for lip augmentation. Patients benefit from results that move naturally with their facial expressions while lasting over time,” said Dr. Ava Shamban, investigator in the trial.

A step forward in lip augmentation

Lip fillers are one of the most requested aesthetic treatments, but many existing products can lead to results that look unnatural or require frequent maintenance. Designed with a unique balance of strength and stretch, RHA® 3 adapts to facial dynamics, helping practitioners achieve natural, elegant and long-lasting outcomes.

This pivotal trial was instrumental in supporting the FDA authorization of RHA® 3 for lip volumization, further expanding the evidence base of the RHA® Collection worldwide.

About RHA® 3

RHA® 3 is part of the TEOSYAL® Resilient Hyaluronic Acid Collection; a range of fillers designed to adapt to facial movement and provide natural-looking results. With its advanced rheological properties, RHA® 3 is especially suited for lips, offering durability and dynamic adaptation with minimal injection volumes.